Bevenopran: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Bevenopran.svg|Bevenopran | |||
</gallery> | |||
Latest revision as of 00:47, 20 February 2025
Bevenopran (also known as CB-5945) is a drug that was under development for the treatment of opioid-induced constipation and irritable bowel syndrome. It works by blocking the peripheral opioid receptors in the gut, which are responsible for the constipating effects of opioids, without affecting the central opioid receptors that provide pain relief.
History[edit]
Bevenopran was developed by Cubist Pharmaceuticals, which was later acquired by Merck & Co.. In 2015, Merck discontinued the development of Bevenopran due to the results of a pre-specified interim analysis of a Phase 3 study.
Mechanism of Action[edit]
Bevenopran is a peripherally acting mu-opioid receptor antagonist (PAMORA). It works by blocking the peripheral opioid receptors in the gut, which are responsible for the constipating effects of opioids, without affecting the central opioid receptors that provide pain relief. This allows for the continued use of opioids for pain management, while reducing their constipating side effects.
Clinical Trials[edit]
Bevenopran underwent Phase 2 and Phase 3 clinical trials for the treatment of opioid-induced constipation. However, the development of the drug was discontinued after a pre-specified interim analysis of a Phase 3 study.
